Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Kabir Mody

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-3254-2990; OpenAlex author ID A5062280376. Sources: OpenAlex.

Their work

Papers
15 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
56
Papers, trials and grants by year

2014: 2 papers · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 5 papers · 2022: 1 paper · 2023: none · 2024: 1 paper

Papers 15

  1. ERBB2 (HER2) amplifications and co-occurring KRAS alterations in the circulating cell-free DNA of pancreatic ductal adenocarcinoma patients and response to HER… Last author DOI 10.3389/fonc.2024.1339302↗
  2. Pharmacotherapeutic options for pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/14656566.2022.2149322↗
  3. Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1002/onco.13717↗
  4. Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer. Co-author DOI 10.1002/psp4.12725↗
  5. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study. Co-author DOI 10.1016/j.ejca.2021.03.028↗
  6. The Increasing Proportion of Early-Stage Pancreatic Cancer between 2004-2013: A SEER Analysis. Co-author DOI 10.1080/07357907.2021.1888386↗
  7. Circulating Cell-Free Tumor DNA in Advanced Pancreatic Adenocarcinoma Identifies Patients With Worse Overall Survival. Co-author DOI 10.3389/fonc.2021.794009↗
  8. Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer. Co-author DOI 10.1136/esmoopen-2019-000668↗
  9. Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic… Co-author DOI 10.1021/acs.bioconjchem.9b00632↗
  10. Safety and efficacy of locoregional therapy for metastatic pancreatic ductal adenocarcinoma to the liver: a single-center experience. Last author DOI 10.21037/jgo.2019.03.13↗
  11. Survival of Patients with Oligometastatic Pancreatic Ductal Adenocarcinoma Treated with Combined Modality Treatment Including Surgical Resection: A Pilot Study. Last author DOI 10.1089/pancan.2018.0011↗
  12. Laparoscopic versus open pancreaticoduodenectomy for pancreatic adenocarcinoma: long-term results at a single institution. Co-author DOI 10.1007/s00464-016-5222-1↗
  13. Laparoscopic Versus Open Distal Pancreatectomy for Pancreatic Adenocarcinoma. Co-author DOI 10.1007/s00268-016-3412-6↗
  14. The effect of neoadjuvant chemoradiation on pancreatic cancer-associated diabetes mellitus. Co-author DOI 10.1097/mpa.0000000000000162↗
  15. Multiorgan Streptococcus milleri Abscesses During FOLFIRINOX Chemotherapy in a Patient With Metastatic Pancreatic Cancer. First author PMID 25276270↗

Closest collaborators

The 25 strongest of 56 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tanios Bekaii‐Saab · 4 shared papers, 2021 · strength 0.45
  2. John Andrew Stauffer · 4 shared papers, 2016–2021 · strength 0.40
  3. Daruka Mahadevan · 2 shared papers, 2022–2024 · strength 0.37
  4. Mitesh J. Borad · 3 shared papers, 2021–2022 · strength 0.36
  5. Horacio J. Asbun · 3 shared papers, 2016–2018 · strength 0.24
  6. Zev A. Wainberg · 2 shared papers, 2021 · strength 0.24
  7. Andrew Peter Dean · 2 shared papers, 2021 · strength 0.24
  8. Bin Zhang · 2 shared papers, 2021 · strength 0.24
  9. Farshid Dayyani · 2 shared papers, 2021 · strength 0.24
  10. Teresa Mercade Macarulla · 2 shared papers, 2021 · strength 0.24
  11. Michael B. Wallace · 2 shared papers, 2018–2021 · strength 0.24
  12. Massimo Raimondo · 2 shared papers, 2018–2021 · strength 0.24
  13. Afsaneh Barzi · 1 shared paper, 2024 · strength 0.22
  14. Andrea Wang‐Gillam · 1 shared paper, 2024 · strength 0.22
  15. Daniel H. Ahn · 2 shared papers, 2021 · strength 0.21
  16. Mohamad Bassam Sonbol · 2 shared papers, 2021 · strength 0.21
  17. Jason Scott Starr · 2 shared papers, 2021 · strength 0.21
  18. Gehan Botrus · 2 shared papers, 2021 · strength 0.21
  19. Pedro Luiz Serrano Usón · 2 shared papers, 2021 · strength 0.21
  20. Alessandro Coppola · 2 shared papers, 2016–2017 · strength 0.16
  21. Sven Peter Oman · 1 shared paper, 2021 · strength 0.16
  22. Juan E. Corral · 1 shared paper, 2021 · strength 0.16
  23. Sreenivasa Rao Chandana · 1 shared paper, 2022 · strength 0.15
  24. Alejandro Recio‐Boiles · 1 shared paper, 2022 · strength 0.15
  25. Muhammad Sardar · 1 shared paper, 2022 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.